PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

Takeda findings may minimise haemophilia treatment side effects

Research from Takeda and Institute Krems Bioanalytics of IMC Krems will help treat patients.

Immune responses against factor VIII (FVIII) – used to treat haemophilia A – are influenced by the microenvironment of antigen-presenting cells.

The findings have emerged from a scientific study conducted in partnership between the Institute Krems Bioanalytics of IMC University of Applied Sciences Krems (IMC Krems) and Takeda.

Haemophilia A is a hereditary bleeding disorder caused by the absence or deficiency of active clotting FVIII in the blood. A major complication of this therapy is the development of a neutralising immune reaction in 30% of patients, therefore rendering the administered FVIII ineffective. The research group, led by the institute deputy head, Dr Christian Lubich, set out to address the ongoing issue.

During the study, a cell culture model was used to investigate the impact of the microenvironment on factor VIII uptake and processing within antigen-presenting cells. It was discovered that observed alterations in protein processing might have profound effects on immune responses to FVIII.

The novel data provided will form the basis for developing future FVIII therapies that elicit minimal immune responses in patients.

Dr Lubich explained: “The experimental design of our cell culture study aimed at taking a closer look at the response of different immune cells in the context of FVIII administration and thereby gaining better insight into the underlying processes.”

He added: “Immunopetidomics is a pioneering method for investigation of the composition and dynamics of proteins presented by antigen-presenting cells with the aid of mass spectrometry. This method can be used, for example, to determine peptides of a pathogen, a tumour cell or, as in this case, a biotherapeutic agent that elicits an immune response.”

IMC Krems specialises in innovative bioanalytical services and the institute focuses on tailor-made immunogenicity assessments.

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026